KR20150048920A - 목시플록사신 염산염의 합성방법 - Google Patents

목시플록사신 염산염의 합성방법 Download PDF

Info

Publication number
KR20150048920A
KR20150048920A KR1020157010216A KR20157010216A KR20150048920A KR 20150048920 A KR20150048920 A KR 20150048920A KR 1020157010216 A KR1020157010216 A KR 1020157010216A KR 20157010216 A KR20157010216 A KR 20157010216A KR 20150048920 A KR20150048920 A KR 20150048920A
Authority
KR
South Korea
Prior art keywords
moxifloxacin hydrochloride
crystalline form
moxifloxacin
hydrochloride according
rti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157010216A
Other languages
English (en)
Korean (ko)
Inventor
다르마라즈 라마찬드라 라오
라젠드라 나라얀라오 칸칸
스리니바스 락스미나라얀 파씨
레비쿠마르 푸파라
마니쉬 강그라데
샤쉬레카 카나쌀라
Original Assignee
씨아이피엘에이 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨아이피엘에이 엘티디. filed Critical 씨아이피엘에이 엘티디.
Publication of KR20150048920A publication Critical patent/KR20150048920A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020157010216A 2006-11-13 2007-11-13 목시플록사신 염산염의 합성방법 Ceased KR20150048920A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1879MU2006 2006-11-13
IN1879/MUM/2006 2006-11-13
PCT/GB2007/004320 WO2008059223A2 (en) 2006-11-13 2007-11-13 Process for the synthesis of moxifloxacin hydrochloride

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097012171A Division KR101539561B1 (ko) 2006-11-13 2007-11-13 목시플록사신 염산염의 합성방법

Publications (1)

Publication Number Publication Date
KR20150048920A true KR20150048920A (ko) 2015-05-07

Family

ID=38947366

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097012171A Expired - Fee Related KR101539561B1 (ko) 2006-11-13 2007-11-13 목시플록사신 염산염의 합성방법
KR1020157010216A Ceased KR20150048920A (ko) 2006-11-13 2007-11-13 목시플록사신 염산염의 합성방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020097012171A Expired - Fee Related KR101539561B1 (ko) 2006-11-13 2007-11-13 목시플록사신 염산염의 합성방법

Country Status (10)

Country Link
US (1) US8198451B2 (enExample)
EP (2) EP2089388B1 (enExample)
JP (2) JP2010509305A (enExample)
KR (2) KR101539561B1 (enExample)
AU (1) AU2007320997B2 (enExample)
CA (1) CA2669427A1 (enExample)
IN (1) IN2014MN02582A (enExample)
NZ (1) NZ576929A (enExample)
WO (1) WO2008059223A2 (enExample)
ZA (1) ZA200903889B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576929A (en) 2006-11-13 2012-07-27 Cipla Ltd Crystalline anhydrous form C of moxifloxacin hydrochloride
CN101817820B (zh) * 2009-07-30 2011-10-05 重庆博腾制药科技股份有限公司 一种盐酸莫西沙星的合成方法
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
CN102309458B (zh) * 2010-07-09 2016-02-03 北京圣医耀科技发展有限责任公司 海藻酸钠交联莫西沙星缓释微球、其制备方法和用途以及含有所述微球的血管靶向栓塞剂
CN102617622B (zh) * 2011-01-31 2016-06-15 深圳信立泰药业股份有限公司 一种制备莫西沙星或其可药用盐及其中间体的方法
CN102276603B (zh) * 2011-07-14 2012-10-24 福建省福抗药业股份有限公司 一种盐酸莫西沙星的清洁制备方法
ITTO20110705A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Procedimento di preparazione della moxifloxacina cloridrato e relativi intermedi
CN102659761B (zh) * 2012-04-27 2017-10-10 常州市亚邦医药研究所有限公司 盐酸贝西沙星的制备方法
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
EP2928892B1 (en) 2012-12-04 2018-03-21 Mankind Pharma Ltd. An improved process for the preparation of moxifloxacin hydrochloride
CN103102341A (zh) * 2012-12-14 2013-05-15 浙江普洛康裕制药有限公司 一种巴洛沙星二水合物的制备方法
CN103012452B (zh) * 2012-12-25 2015-12-02 浙江新和成股份有限公司 一种莫西沙星及其盐酸盐的制备方法
CN104098561B (zh) * 2013-04-10 2016-01-20 山东省生物医药科学院 一种适合工业化生产的制备高光学纯度盐酸莫西沙星的方法
CN104031043B (zh) * 2014-05-28 2016-03-16 成都克莱蒙医药科技有限公司 一种盐酸莫西沙星合成方法
CN104860944A (zh) * 2015-06-09 2015-08-26 内蒙古东北六药集团有限公司 盐酸莫西沙星的生产方法
CN105237535A (zh) * 2015-11-15 2016-01-13 青岛麦瑞特医药技术有限公司 一种制备盐酸莫西沙星的方法
CN105669671A (zh) * 2016-03-10 2016-06-15 陈红 一种盐酸莫西沙星的制备方法
CN110143959B (zh) * 2019-05-10 2022-04-26 广西两面针亿康药业股份有限公司 一种盐酸莫西沙星的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8810667A8 (en) * 1987-04-08 1996-04-30 Chinoin Gyogyszer Es Vegyeszet Anhydride of quinoline carboxylic acid of boron acid and process for their production.
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH0778065B2 (ja) * 1990-07-06 1995-08-23 杏林製薬株式会社 （６，７―置換―８―アルコキシ―１―シクロプロピル―１，４―ジヒドロ―４―オキソ―３―キノリンカルボン酸―ｏ▲上３▼，ｏ▲上４▼）ビス（アシルオキシ―ｏ）ホウ素化合物及びその塩並びにその製造方法
TW209865B (enExample) 1992-01-10 1993-07-21 Bayer Ag
ES2077490B1 (es) * 1992-11-18 1996-10-16 Marga Investigacion Esteres trimetilsililicos y solvatos de quelatos de acidos quinolin-3-carboxilicos. preparacion y aplicacion al proceso de quinolonas.
DE4342186A1 (de) 1993-12-10 1995-06-14 Bayer Ag Eintopfverfahren zur Herstellung von 3-Chinoloncarbonsäurederivaten
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE19821039A1 (de) * 1998-05-11 1999-11-18 Bayer Ag Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
CN1184221C (zh) * 2001-08-08 2005-01-12 中国医学科学院医药生物技术研究所 有7－(7－氨甲基－5－氮杂螺[2,4]庚烷)取代基的新喹啉羧酸衍生物及其制备方法
EP2113505A1 (en) 2003-04-09 2009-11-04 Dr. Reddy's Laboratories, Ltd. A crystalline form III of anhydrous moxifloxacin hydrochloride and processes for the preparation thereof
US20060264635A1 (en) 2003-08-05 2006-11-23 Chava Satyanarayana Process for the preparation of moxifloxacin hydrochloride
ES2319125T3 (es) 2003-11-20 2009-05-04 Chemi S.P.A. Polimorfos del clorhidrato del acido 1-ciclopropil-7-((s,s)-2,8-diazadiciclo(4.3.0)-non-8-il)-6-fluoro-1,4-dihidro-8-metoxi-4-oxo-3-quinolina carboxilico y metodos para la preparacion de los mismos.
US7320006B2 (en) * 2004-11-12 2008-01-15 Computer Sciences Corporation Hierarchical database management
WO2006134491A2 (en) * 2005-06-14 2006-12-21 Aurobindo Pharma Limited New crystalline form of moxifloxacin hydrochloride and process for its preparation
WO2007010555A2 (en) 2005-07-15 2007-01-25 Msn Laboratories Limited Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof
ES2284380B1 (es) * 2006-03-10 2008-11-01 Quimica Sintetica S.A. Procedimiento para la preparacion de moxifloxacino y moxifloxacino clorhidrato.
NZ576929A (en) 2006-11-13 2012-07-27 Cipla Ltd Crystalline anhydrous form C of moxifloxacin hydrochloride

Also Published As

Publication number Publication date
EP2089388A2 (en) 2009-08-19
AU2007320997B2 (en) 2012-11-08
JP2014122223A (ja) 2014-07-03
CA2669427A1 (en) 2008-05-22
AU2007320997A1 (en) 2008-05-22
US8198451B2 (en) 2012-06-12
JP2010509305A (ja) 2010-03-25
ZA200903889B (en) 2010-03-31
KR101539561B1 (ko) 2015-07-27
EP2089388B1 (en) 2014-01-29
JP5774732B2 (ja) 2015-09-09
US20100152229A1 (en) 2010-06-17
EP2474547A3 (en) 2012-07-25
EP2474547A2 (en) 2012-07-11
IN2014MN02582A (enExample) 2015-09-11
KR20090090337A (ko) 2009-08-25
NZ576929A (en) 2012-07-27
WO2008059223A2 (en) 2008-05-22
WO2008059223A3 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
KR101539561B1 (ko) 목시플록사신 염산염의 합성방법
JP2742248B2 (ja) ７−（４−アミノメチル−３−オキシム）ピロリジン置換体を持つ新規なキノリンカルボン酸誘導体およびその製造方法
HU219488B (hu) Kinolon-karbonsavszármazék, ezt tartalmazó gyógyszerkészítmény és eljárás előállításukra
EP0375658A1 (en) Quinoline derivatives and processes for preparation thereof
DK172077B1 (da) 6-Fluor-7-(4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinolin-3-carboxylsyre-derivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende disse forbindelser
WO2007010555A2 (en) Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof
EP3042893B1 (en) Novel crystalline arylalkylamine compound and method for producing same
WO2006134491A2 (en) New crystalline form of moxifloxacin hydrochloride and process for its preparation
JPH0635458B2 (ja) ピリドンカルボン酸誘導体、そのエステルおよびその塩
US6576764B2 (en) Synthesis and crystallization of piperazine ring-containing compounds
JPWO1995021163A1 (ja) ２環性アミノ基で置換されたピリドンカルボン酸誘導体、そのエステルおよびその塩ならびにこれらの中間体たる２環性アミン
EP3679030B1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
CN101450938B (zh) 7-(4-肟基-3-氨基-3-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法
EP0216323A2 (en) Quinolonecarboxylic acid derivatives and their preparation
US20240239791A1 (en) Processes for the synthesis of valbenazine
KR0174373B1 (ko) 7-(4-아미노메틸-4-알킬-3-알킬옥심)피롤리딘 치환체를 갖는 신규 퀴놀린 카르복실산 유도체 및 그의 제조방법
EP0221541A2 (en) Quinolonecarboxylic acid derivatives and their preparation
JPH0848629A (ja) ピリドンカルボン酸誘導体およびそれを有効成分とする抗ピロリ菌剤
CN101450947B (zh) 7-(3-肟基-4-氨基-4-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法
KR0167486B1 (ko) 6-메틸-5-아미노 퀴놀린 카복실산 유도체 및 그의 제조방법
KR0150742B1 (ko) 신규한 퀴놀린 카르복실산 유도체 및 그의 제조방법
CN101353348A (zh) 7-[4-(胺甲基)-4-氟-3-(烷氧亚氨基)吡咯烷-1-基]取代的喹啉羧酸衍生物及其制备方法
CN1240431A (zh) N－[2－(二甲氨基)乙基]吖啶－4－甲酰胺的制备方法
US20070032505A1 (en) Crystalline form of gatifloxacin
JPWO1996001260A1 (ja) ピリドンカルボン酸誘導体、そのエステルおよびその塩ならびにこれらの合成中間体

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150421

Application number text: 1020097012171

Filing date: 20090612

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150716

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150716

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I